Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

BioCorRx (BICX) Cash & Equivalents (2016 - 2025)

BioCorRx (BICX) has disclosed Cash & Equivalents for 16 consecutive years, with $139360.0 as the latest value for Q4 2025.

  • Quarterly Cash & Equivalents rose 58.3% to $139360.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $139360.0 through Dec 2025, up 58.3% year-over-year, with the annual reading at $139360.0 for FY2025, 58.3% up from the prior year.
  • Cash & Equivalents hit $139360.0 in Q4 2025 for BioCorRx, down from $287688.0 in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $1.9 million in Q1 2021 to a low of $90.0 in Q3 2024.
  • Historically, Cash & Equivalents has averaged $264221.2 across 5 years, with a median of $111666.5 in 2022.
  • Biggest five-year swings in Cash & Equivalents: plummeted 99.94% in 2024 and later skyrocketed 319553.33% in 2025.
  • Year by year, Cash & Equivalents stood at $85838.0 in 2021, then decreased by 20.06% to $68615.0 in 2022, then dropped by 4.94% to $65222.0 in 2023, then skyrocketed by 34.97% to $88033.0 in 2024, then skyrocketed by 58.3% to $139360.0 in 2025.
  • Business Quant data shows Cash & Equivalents for BICX at $139360.0 in Q4 2025, $287688.0 in Q3 2025, and $111872.0 in Q2 2025.